Findings from this trial reinforce the preclinical data supporting the approval of the LP.8.1-adapted COVID-19 vaccine for the 2025-2026 season. Topline results were announced from a phase 3 trial ...
The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback